Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

1.90SEK
9 Dec 2016
Change (% chg)

-0.27kr (-12.44%)
Prev Close
2.17kr
Open
2.17kr
Day's High
2.18kr
Day's Low
1.78kr
Volume
3,102,680
Avg. Vol
1,246,018
52-wk High
3.92kr
52-wk Low
1.77kr

BINV.ST

Chart for BINV.ST

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for BINV.ST.

Overall

Beta: 0.46
Market Cap(Mil.): kr537.17
Shares Outstanding(Mil.): 282.72
Dividend: --
Yield (%): --

Financials

  BINV.ST Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -0.31 -- --
ROI: -65.11 -0.36 15.24
ROE: -65.11 -0.94 16.58

BRIEF-Bioinvent posts Q3 loss after tax of 29 mln SEK

* Q3 earnings after tax SEK -29 (-23) million. Further company coverage: (Reporting By Simon Johnson)

Oct 25 2016

BRIEF-Bioinvent says granted additional patent protection for BI-505

* Bioinvent expands patent approvals for its lead clinical immuno-oncology programme in multiple myeloma, bi-505

Sep 19 2016

BRIEF-BioInvent extends contract with existing customer, expects SEK 8 mln in revenue

* BioInvent extends manufacturing services contract with major global pharmaceutical client; expects to generate approximately SEK 8 million in revenue Further company coverage: (Reporting by Stockholm Newsroom)

Aug 29 2016

BRIEF-BioInvent Q2 net loss widens, reports higher sales

* Says net sales for april-june 2016 amounted to sek 10 (3.7) million.

Jul 26 2016

Earnings vs. Estimates